BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA)...
“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...
Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients...
Akorn Operating Company LLC has filed Chapter 7 bankruptcy on February 23, 2023. In connection with that filing, the company has ceased and shutdow...
PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Austr...
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer a...
Aquavit will begin its Phase II/Phase III trials for DTX-023 (aqubotulinumtoxinA) and DTX-024 (aqubotulinumtoxinA with intradermal microinjector) under the...
Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Res...
Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...
Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Ph...
Corning Incorporated announced the launch of its Advanced Flow Pharmaceutical Technology (AFPT) services business to help contract development m...
European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + O...
The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete r...
© 2025 Biopharma Boardroom. All Rights Reserved.